J&J Jumps as UBS Lifts Its Target to $320
Yahoo Finance ·
J&J Jumps as UBS Lifts Its Target to $320 Khac Phu Nguyen Wed, September 2, 2026 at 12:42 PM EDT 1 min read UBS JNJ ^DJI This article first appeared on GuruFocus . Johnson & Johnson ( NYSE:JNJ ), the pharmaceutical and medical-technology powerhouse, surged roughly 1.2% to $274.395 Wednesday after UBS cranked its price target from $280 to $320. Barron's reported that J&J became the Dow's biggest point booster in early trading. Wall Street heard the message loud and clear: UBS sees more fuel in this rally. Warning! GuruFocus has detected 3 Warning Signs with MU. Is JNJ fairly valued? Test your thesis with our free DCF calculator. The firm kept its Buy rating, pointing to faster growth and more value hiding inside J&J's pharmaceutical pipeline. The operating engine is already delivering. J&J's second-quarter results showed sales climbing 6.6% to $25.3 billion, while management raised its 2026 sales midpoint to $101.1 billion and adjusted earnings guidance to $11.68 per share. But the valuation is flashing yellow. The picture shows J&J trading 42.25% above its $192.90 GF Value, leaving little room for pipeline stumbles. UBS's $320 target still points to roughly 16.6% upside from $274.395, but J&J must earn every dollar. Clinical wins, regulatory approvals and successful launches now matter more than another round of multiple expansion.
DYAX Investor Sentiment
Bullish (Long) 43% · Bearish (Short) 57%
446 participants
Related News
- Bitcoin ETFs Just Posted Their Best Month of 2026. Is the Bitcoin Rally Here to Stay?
- Why The Trade Desk Stock Rallied Today
- Nvidia Leads Chip Stocks Higher Amid Renewed Confidence In AI Spending
- Palantir stock tumbles as Google encroaches on defense AI market
- Enhanced geothermal notches another win as Google buys 400 MW from Fervo
- Barrick Mining (B) reportedly considering delaying its North America Gold IPO to 2027, according to reports
